NCT00628628View on ClinicalTrials.gov

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Tumor Lysis Syndrome
Interventions
DRUG

As Needed Rasburicase

.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.

DRUG

Fixed Dose Rasburicase

.15 mg/kg IV Over 30 Minutes Daily

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00628628 - Rasburicase in Patients at Risk for Tumor Lysis Syndrome | Biotech Hunter | Biotech Hunter